Cargando…
Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma
This pilot study explored the value of localized index node removal after neoadjuvant immunotherapy in patients with stage III melanoma, for use as a response indicator to guide the extent of completion lymph node dissection. [Image: see text] Promising technology
Autores principales: | Schermers, B., Franke, V., Rozeman, E. A., van de Wiel, B. A., Bruining, A., Wouters, M. W., van Houdt, W. J., ten Haken, B., Muller, S. H., Bierman, C., Ruers, T. J. M., Blank, C. U., van Akkooi, A. C. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593699/ https://www.ncbi.nlm.nih.gov/pubmed/30882901 http://dx.doi.org/10.1002/bjs.11168 |
Ejemplares similares
-
Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
por: van Akkooi, Alexander C. J., et al.
Publicado: (2022) -
Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer
por: Simons, J. M., et al.
Publicado: (2019) -
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
por: Reijers, Irene L.M., et al.
Publicado: (2023) -
Increase in invasive group A streptococcal (Streptococcus pyogenes) infections (iGAS) in young children in the Netherlands, 2022
por: de Gier, Brechje, et al.
Publicado: (2023) -
Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial
por: Rohaan, Maartje W., et al.
Publicado: (2022)